Posted by Michael Wonder on 12 Jul 2021
Minister for Health announces HSE approval to reimburse patisiran (Onpattro)
12 July 2021 - The Minister for Health, Stephen Donnelly TD is pleased to announce that the drug patisiran (Onpattro) has been approved by the HSE for reimbursement in the treatment of hereditary transthyretin mediated amyloidosis.
Hereditary transthyretin mediated amyloidosis is an inherited, rare, life-limiting, multi-systemic disease where there are limited treatment options currently available.
In order for the HSE to recommend in favour of reimbursement of patisiran (Onpattro), the HSE has undertaken considerable engagement and negotiation with the manufacturer Alnylam over a protracted period.
